Trinity Biotech plc Logo

Trinity Biotech plc

TRIB

(2.0)
Stock Price

0,93 USD

-42.41% ROA

95.19% ROE

-0.66x PER

Market Cap.

16.073.749,00 USD

-282.78% DER

0% Yield

-38.02% NPM

Trinity Biotech plc Stock Analysis

Trinity Biotech plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Trinity Biotech plc Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (924.98%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-1.29x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a minimal amount of debt (-592%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Graham Number

The company's Graham number suggests that its stock price is underestimated, implying that it may present a compelling investment opportunity.

5 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (5) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

6 ROA

The stock's ROA (-55.68%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

10 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

11 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Trinity Biotech plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Trinity Biotech plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Trinity Biotech plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Trinity Biotech plc Revenue
Year Revenue Growth
1993 2.400.000
1994 5.200.000 53.85%
1995 9.900.000 47.47%
1996 7.200.000 -37.5%
1997 16.800.000 57.14%
1998 23.200.000 27.59%
1999 26.104.623 11.13%
2000 29.742.942 12.23%
2001 37.064.573 19.75%
2002 51.979.756 28.69%
2003 65.675.398 20.85%
2004 79.944.000 17.85%
2005 98.560.000 18.89%
2006 118.674.000 16.95%
2007 143.617.000 17.37%
2008 140.139.000 -2.48%
2009 125.907.000 -11.3%
2010 89.635.000 -40.47%
2011 77.948.000 -14.99%
2012 82.510.000 5.53%
2013 91.216.000 9.54%
2014 104.871.000 13.02%
2015 100.195.000 -4.67%
2016 99.611.000 -0.59%
2017 99.140.000 -0.48%
2018 97.035.000 -2.17%
2019 90.435.000 -7.3%
2020 101.980.000 11.32%
2021 92.965.000 -9.7%
2022 74.779.000 -24.32%
2023 55.592.000 -34.51%
2023 56.832.000 2.18%
2024 63.372.000 10.32%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Trinity Biotech plc Research and Development Expenses
Year Research and Development Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 1.800.000 100%
1998 2.600.000 30.77%
1999 2.448.372 -6.19%
2000 2.681.220 8.68%
2001 2.779.729 3.54%
2002 4.470.745 37.82%
2003 5.210.039 14.19%
2004 4.641.000 -12.26%
2005 6.070.000 23.54%
2006 6.696.000 9.35%
2007 13.709.000 51.16%
2008 7.544.000 -81.72%
2009 7.341.000 -2.77%
2010 4.603.000 -59.48%
2011 3.206.000 -43.57%
2012 3.130.000 -2.43%
2013 3.691.000 15.2%
2014 4.290.000 13.96%
2015 5.068.000 15.35%
2016 5.041.000 -0.54%
2017 5.658.000 10.9%
2018 5.369.000 -5.38%
2019 5.325.000 -0.83%
2020 5.080.000 -4.82%
2021 4.497.000 -12.96%
2022 4.138.000 -8.68%
2023 4.932.000 16.1%
2023 4.379.000 -12.63%
2024 3.964.000 -10.47%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Trinity Biotech plc General and Administrative Expenses
Year General and Administrative Expenses Growth
1993 0
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 494.000 100%
2010 26.929.000 98.17%
2011 22.048.000 -22.14%
2012 22.425.000 1.68%
2013 24.879.000 9.86%
2014 28.442.000 12.53%
2015 28.016.000 -1.52%
2016 30.800.000 9.04%
2017 30.854.000 0.18%
2018 29.499.000 -4.59%
2019 27.584.000 -6.94%
2020 25.074.000 -10.01%
2021 24.683.000 -1.58%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Trinity Biotech plc EBITDA
Year EBITDA Growth
1993 -3.800.000
1994 -1.600.000 -137.5%
1995 -2.600.000 38.46%
1996 -300.000 -766.67%
1997 1.600.000 118.75%
1998 3.700.000 56.76%
1999 6.265.602 40.95%
2000 9.780.687 35.94%
2001 8.699.588 -12.43%
2002 10.268.438 15.28%
2003 12.959.531 20.77%
2004 10.130.000 -27.93%
2005 10.698.000 5.31%
2006 8.089.000 -32.25%
2007 -22.026.000 136.72%
2008 -71.469.000 69.18%
2009 14.107.000 606.62%
2010 15.381.000 8.28%
2011 18.212.000 15.54%
2012 19.446.000 6.35%
2013 19.173.000 -1.42%
2014 18.135.000 -5.72%
2015 26.360.000 31.2%
2016 9.920.000 -165.73%
2017 6.286.000 -57.81%
2018 7.418.000 15.26%
2019 5.766.000 -28.65%
2020 22.183.000 74.01%
2021 15.898.000 -39.53%
2022 -8.277.000 292.07%
2023 -13.964.000 40.73%
2023 -13.484.000 -3.56%
2024 -6.108.000 -120.76%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Trinity Biotech plc Gross Profit
Year Gross Profit Growth
1993 200.000
1994 800.000 75%
1995 2.200.000 63.64%
1996 1.700.000 -29.41%
1997 5.900.000 71.19%
1998 8.800.000 32.95%
1999 13.087.537 32.76%
2000 16.302.411 19.72%
2001 18.917.808 13.83%
2002 25.611.063 26.13%
2003 32.798.447 21.91%
2004 40.256.000 18.53%
2005 47.182.000 14.68%
2006 50.784.000 7.09%
2007 55.249.000 8.08%
2008 62.494.000 11.59%
2009 57.016.000 -9.61%
2010 43.945.000 -29.74%
2011 40.128.000 -9.51%
2012 42.253.000 5.03%
2013 45.911.000 7.97%
2014 50.347.000 8.81%
2015 46.245.000 -8.87%
2016 43.093.000 -7.31%
2017 41.889.000 -2.87%
2018 41.449.000 -1.06%
2019 38.120.000 -8.73%
2020 48.580.000 21.53%
2021 38.077.000 -27.58%
2022 22.048.000 -72.7%
2023 20.120.000 -9.58%
2023 18.504.000 -8.73%
2024 22.064.000 16.13%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Trinity Biotech plc Net Profit
Year Net Profit Growth
1993 -3.400.000
1994 -3.300.000 -3.03%
1995 -800.000 -312.5%
1996 -900.000 11.11%
1997 1.200.000 175%
1998 2.600.000 53.85%
1999 4.915.697 47.11%
2000 4.823.465 -1.91%
2001 1.449.348 -232.8%
2002 5.010.317 71.07%
2003 5.797.474 13.58%
2004 5.166.000 -12.22%
2005 5.280.000 2.16%
2006 3.276.000 -61.17%
2007 -35.372.000 109.26%
2008 -77.778.000 54.52%
2009 11.824.000 757.8%
2010 60.418.000 80.43%
2011 15.593.000 -287.47%
2012 17.341.000 10.08%
2013 10.337.000 -67.76%
2014 17.213.000 39.95%
2015 21.796.000 21.03%
2016 -100.626.000 121.66%
2017 -40.270.000 -149.88%
2018 2.390.000 1784.94%
2019 -4.066.000 158.78%
2020 -6.013.000 32.38%
2021 875.000 787.2%
2022 -41.002.000 102.13%
2023 -23.952.000 -71.18%
2023 -24.018.000 0.27%
2024 -27.028.000 11.14%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Trinity Biotech plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1993 -2
1994 -1 -100%
1995 0 0%
1996 0 0%
1997 1 100%
1998 2 0%
1999 3 50%
2000 2 0%
2001 1 0%
2002 2 100%
2003 2 50%
2004 2 -100%
2005 0 0%
2006 0 0%
2007 -9 100%
2008 -19 52.63%
2009 2 1050%
2010 3 0%
2011 1 0%
2012 1 0%
2013 0 0%
2014 1 0%
2015 1 0%
2016 -22 100%
2017 -9 -133.33%
2018 1 0%
2019 -1 0%
2020 -1 100%
2021 0 0%
2022 -6 100%
2023 -1 0%
2023 -3 100%
2024 -3 -50%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Trinity Biotech plc Free Cashflow
Year Free Cashflow Growth
1993 -3.200.000
1994 -3.200.000 0%
1995 -900.000 -255.56%
1996 -6.100.000 85.25%
1997 -9.500.000 35.79%
1998 -3.800.000 -150%
1999 2.375.796 259.95%
2000 1.847.507 -28.59%
2001 3.717.496 50.3%
2002 9.135.054 59.31%
2003 -251.547 3731.55%
2004 -3.647.000 93.1%
2005 5.170.000 170.54%
2006 -3.468.000 249.08%
2007 -764.000 -353.93%
2008 -1.965.000 61.12%
2009 4.148.000 147.37%
2010 14.056.000 70.49%
2011 11.249.000 -24.95%
2012 7.136.000 -57.64%
2013 -10.239.000 169.69%
2014 -8.185.000 -25.09%
2015 -10.381.000 21.15%
2016 -8.506.000 -22.04%
2017 -4.255.000 -99.91%
2018 -10.351.000 58.89%
2019 -9.881.000 -4.76%
2020 13.557.000 172.88%
2021 4.547.000 -198.15%
2022 -6.898.000 165.92%
2023 -4.982.000 -38.46%
2023 -21.883.000 77.23%
2024 -6.247.000 -250.3%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Trinity Biotech plc Operating Cashflow
Year Operating Cashflow Growth
1993 -2.400.000
1994 -3.100.000 22.58%
1995 -800.000 -287.5%
1996 -3.600.000 77.78%
1997 -1.400.000 -157.14%
1998 -1.000.000 -40%
1999 3.821.524 126.17%
2000 3.021.428 -26.48%
2001 5.060.866 40.3%
2002 11.652.036 56.57%
2003 3.604.522 -223.26%
2004 42.000 -8482.2%
2005 9.209.000 99.54%
2006 7.368.000 -24.99%
2007 15.349.000 52%
2008 10.729.000 -43.06%
2009 14.732.000 27.17%
2010 23.073.000 36.15%
2011 20.484.000 -12.64%
2012 20.056.000 -2.13%
2013 11.706.000 -71.33%
2014 15.752.000 25.69%
2015 12.335.000 -27.7%
2016 13.771.000 10.43%
2017 12.112.000 -13.7%
2018 6.935.000 -74.65%
2019 5.474.000 -26.69%
2020 23.755.000 76.96%
2021 13.238.000 -79.45%
2022 -921.000 1537.35%
2023 -4.418.000 79.15%
2023 -19.179.000 76.96%
2024 -3.080.000 -522.69%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Trinity Biotech plc Capital Expenditure
Year Capital Expenditure Growth
1993 800.000
1994 100.000 -700%
1995 100.000 0%
1996 2.500.000 96%
1997 8.100.000 69.14%
1998 2.800.000 -189.29%
1999 1.445.728 -93.67%
2000 1.173.921 -23.15%
2001 1.343.370 12.61%
2002 2.516.982 46.63%
2003 3.856.069 34.73%
2004 3.689.000 -4.53%
2005 4.039.000 8.67%
2006 10.836.000 62.73%
2007 16.113.000 32.75%
2008 12.694.000 -26.93%
2009 10.584.000 -19.94%
2010 9.017.000 -17.38%
2011 9.235.000 2.36%
2012 12.920.000 28.52%
2013 21.945.000 41.13%
2014 23.937.000 8.32%
2015 22.716.000 -5.38%
2016 22.277.000 -1.97%
2017 16.367.000 -36.11%
2018 17.286.000 5.32%
2019 15.355.000 -12.58%
2020 10.198.000 -50.57%
2021 8.691.000 -17.34%
2022 5.977.000 -45.41%
2023 564.000 -959.75%
2023 2.704.000 79.14%
2024 3.167.000 14.62%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Trinity Biotech plc Equity
Year Equity Growth
1993 3.100.000
1994 1.300.000 -138.46%
1995 7.500.000 82.67%
1996 10.600.000 29.25%
1997 7.100.000 -49.3%
1998 14.600.000 51.37%
1999 22.721.817 35.74%
2000 55.042.649 58.72%
2001 56.531.571 2.63%
2002 62.908.242 10.14%
2003 80.261.927 21.62%
2004 116.138.000 30.89%
2005 133.618.000 13.08%
2006 167.262.000 20.11%
2007 136.845.000 -22.23%
2008 65.905.000 -107.64%
2009 79.344.000 16.94%
2010 141.287.000 43.84%
2011 151.332.000 6.64%
2012 169.380.000 10.66%
2013 183.011.000 7.45%
2014 196.975.000 7.09%
2015 213.888.000 7.91%
2016 108.727.000 -96.72%
2017 65.196.000 -66.77%
2018 44.054.000 -47.99%
2019 4.713.000 -834.73%
2020 -2.219.000 312.39%
2021 -319.000 -595.61%
2022 -2.176.000 85.34%
2023 -23.949.000 90.91%
2023 -11.380.000 -110.45%
2024 -29.400.000 61.29%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Trinity Biotech plc Assets
Year Assets Growth
1993 4.900.000
1994 3.100.000 -58.06%
1995 9.200.000 66.3%
1996 13.400.000 31.34%
1997 24.600.000 45.53%
1998 45.000.000 45.33%
1999 45.042.295 0.09%
2000 67.230.672 33%
2001 77.029.213 12.72%
2002 89.267.571 13.71%
2003 118.091.489 24.41%
2004 150.828.000 21.7%
2005 184.602.000 18.3%
2006 249.131.000 25.9%
2007 215.979.000 -15.35%
2008 129.509.000 -66.77%
2009 132.445.000 2.22%
2010 160.874.000 17.67%
2011 171.499.000 6.2%
2012 197.407.000 13.12%
2013 226.486.000 12.84%
2014 242.840.000 6.73%
2015 358.959.000 32.35%
2016 249.592.000 -43.82%
2017 192.615.000 -29.58%
2018 151.235.000 -27.36%
2019 131.071.000 -15.38%
2020 130.397.000 -0.52%
2021 118.895.000 -9.67%
2022 92.104.000 -29.09%
2023 59.435.000 -54.97%
2023 71.990.000 17.44%
2024 94.355.000 23.7%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Trinity Biotech plc Liabilities
Year Liabilities Growth
1993 1.800.000
1994 1.800.000 0%
1995 1.700.000 -5.88%
1996 2.800.000 39.29%
1997 17.500.000 84%
1998 30.400.000 42.43%
1999 22.320.478 -36.2%
2000 12.188.023 -83.13%
2001 20.497.642 40.54%
2002 26.359.329 22.24%
2003 37.829.562 30.32%
2004 34.690.000 -9.05%
2005 50.984.000 31.96%
2006 81.869.000 37.72%
2007 79.134.000 -3.46%
2008 63.604.000 -24.42%
2009 53.101.000 -19.78%
2010 19.587.000 -171.1%
2011 20.167.000 2.88%
2012 28.027.000 28.04%
2013 43.475.000 35.53%
2014 45.865.000 5.21%
2015 145.071.000 68.38%
2016 140.865.000 -2.99%
2017 127.419.000 -10.55%
2018 107.181.000 -18.88%
2019 126.358.000 15.18%
2020 132.616.000 4.72%
2021 119.214.000 -11.24%
2022 94.280.000 -26.45%
2023 83.384.000 -13.07%
2023 83.370.000 -0.02%
2024 123.755.000 32.63%

Trinity Biotech plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
6.2
Net Income per Share
-2.36
Price to Earning Ratio
-0.66x
Price To Sales Ratio
0.27x
POCF Ratio
-1.09
PFCF Ratio
-0.82
Price to Book Ratio
-0.5
EV to Sales
1.77
EV Over EBITDA
-9.62
EV to Operating CashFlow
-7.69
EV to FreeCashFlow
-5.29
Earnings Yield
-1.51
FreeCashFlow Yield
-1.22
Market Cap
0,02 Bil.
Enterprise Value
0,10 Bil.
Graham Number
12.83
Graham NetNet
-9.9

Income Statement Metrics

Net Income per Share
-2.36
Income Quality
0.61
ROE
0.95
Return On Assets
-0.24
Return On Capital Employed
-0.19
Net Income per EBT
1.01
EBT Per Ebit
1.74
Ebit per Revenue
-0.22
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.07
Stock Based Compensation to Revenue
0.01
Gross Profit Margin
0.32
Operating Profit Margin
-0.22
Pretax Profit Margin
-0.38
Net Profit Margin
-0.38

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.43
Free CashFlow per Share
-2.08
Capex to Operating CashFlow
-0.45
Capex to Revenue
0.1
Capex to Depreciation
4
Return on Invested Capital
-0.24
Return on Tangible Assets
-0.42
Days Sales Outstanding
110.22
Days Payables Outstanding
211.85
Days of Inventory on Hand
210.77
Receivables Turnover
3.31
Payables Turnover
1.72
Inventory Turnover
1.73
Capex per Share
0.65

Balance Sheet

Cash per Share
0,56
Book Value per Share
-3,11
Tangible Book Value per Share
-7.52
Shareholders Equity per Share
-3.11
Interest Debt per Share
9.51
Debt to Equity
-2.83
Debt to Assets
0.88
Net Debt to EBITDA
-8.14
Current Ratio
1.78
Tangible Asset Value
-0,07 Bil.
Net Current Asset Value
-0,08 Bil.
Invested Capital
65906000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.44
Average Receivables
0,02 Bil.
Average Payables
0,02 Bil.
Average Inventory
22800500
Debt to Market Cap
5.17

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Trinity Biotech plc Dividends
Year Dividends Growth
2011 0
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%

Trinity Biotech plc Profile

About Trinity Biotech plc

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

CEO
Mr. John Gillard
Employee
380
Address
IDA Business Park
Bray, A98 H5C8

Trinity Biotech plc Executives & BODs

Trinity Biotech plc Executives & BODs
# Name Age
1 Ms. Eibhlin Kelly
Chief Information Officer
70
2 Dr. Gary Keating Ph.D.
Chief Technology Officer
70
3 Ms. Louise Tallon
Chief Financial Officer & Chief Accounting Officer
70
4 Mr. Colm Molloy
Group Director of Human Resources & Culture
70
5 Mr. Adrian Donohue
Chief Commercial Officer
70
6 Dr. James Walsh Ph.D.
Executive Director of Business Development & Executive Director
70
7 Mr. John Gillard
President, Chief Executive Officer, Company Secretary & Director
70
8 Mr. Ronan O'Caoimh
Founder, Director & Executive Advisor
70
9 Ms. Jacqueline O'Neill
Director of Operations
70

Trinity Biotech plc Competitors